Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma
KCT0008625Phase 2Not yet recruiting
- Sponsor
- Yonsei University Health System
- Start
- Aug 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pazopanib, pembrolizumab in soft tissue sarcoma (STS), sponsored by Yonsei University Health System. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
pazopanibpembrolizumab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on KCT0008625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008625.